Albert Vanamburg, MD
Medical Oncology · Chesterfield, MONPI 1306804489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,304 and has fallen 69.3% since, to $401 in 2025. That places this record below the midpoint for medical oncology clinicians in MO, where the typical reported total is $3,595.
Across 166 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$375
- Pfizer$217
- E.r. Squibb & Sons, L.L.C.$202
- Bristol Myers Squibb$197
- Merck$182
- AstraZeneca$165
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,85494%
- Education$1816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $375 |
| Pfizer | 13 | $217 |
| E.r. Squibb & Sons, L.L.C. | 12 | $202 |
| Bristol Myers Squibb | 20 | $197 |
| Merck | 9 | $182 |
| AstraZeneca | 9 | $165 |
| Incyte Corporation | 5 | $164 |
| Daiichi Sankyo Inc. | 8 | $141 |
| Johnson & Johnson | 8 | $133 |
| Eisai Inc. | 5 | $109 |
| EMD Serono, Inc. | 4 | $93 |
| Genentech USA, Inc. | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Amgen | 4 | $77 |
| Gilead(2 entities) | 3 | $69 |
| AbbVie | 2 | $58 |
| Puma Biotechnology, Inc. | 3 | $48 |
| GSK | 2 | $45 |
| Karyopharm Therapeutics Inc. | 2 | $45 |
| Tersera Therapeutics LLC | 2 | $38 |
| Taiho Oncology, Inc. | 2 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $37 |
| Servier Pharmaceuticals LLC | 2 | $37 |
| Astellas Pharma US Inc | 2 | $29 |
| Exelixis Inc. | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Sanofi | 1 | $20 |
| Fennec Pharmaceuticals, Inc. | 2 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Octapharma USA, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Tesaro, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $16 |
| Verastem, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| CTI Biopharma Corp. | 1 | $13 |
How this compares
$3,035 in reported general payments places this provider in the 45th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 19 | $231,603 |
| RevlimidLenalidomide | 12 | $213,842 |
| VenclextaVenetoclax | 16 | $71,565 |
| EliquisApixaban | 22 | $27,674 |
| XareltoRivaroxaban | 22 | $17,143 |
| Anagrelide Hcl | 15 | $1,369 |
| Hydroxyurea | 51 | $1,182 |
| Tamoxifen Citrate | 21 | $668 |
| ValacyclovirValacyclovir Hcl | 14 | $633 |
| Ondansetron Hcl | 26 | $424 |
| Dexamethasone | 15 | $328 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $213 |
| Acyclovir | 19 | $167 |
| Prochlorperazine Maleate | 16 | $137 |
| Allopurinol | 12 | $123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $197 | $213,84212 claims |
| AbbVieVenclexta | $58 | $71,56516 claims |
| PfizerEliquis | $217 | $27,67422 claims |
| Johnson & JohnsonXarelto | $133 | $17,14322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Chesterfield
- Leonid ShunyakovBolivar$2.1M
- Timothy PluardKansas City$664K
- Brad KahlSaint Louis$336K
- Michael NaughtonCape Girardeau$249K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.